SARS-CoV-2 PCR Assay Now Approved for Human Saliva Specimens

Validation of its CE-IVD UltraGene® Combo2Screen SARS-CoV-2 qPCR assay to be used straight from non-invasive fluid saliva samples and allowing for broad population screening.

Creatv Microtech Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer (NSCLC) using a Simple Blood Test

“We are delighted to present a method to stratify patients responding to immunotherapy by a single tube of blood collected after completion of CRT,” said Dr. Cha-Mei Tang, CEO of Creatv. “Early identification of patients that do not respond to immunotherapy will reduce unnecessary patient suffering from ineffective and costly treatment, allowing patients to proceed to alternative therapies.” Currently, no other blood test can predict immunotherapy treatment response for lung cancer.

SOLIUS White Paper Released: Explores Potential Impact of Vitamin D On COVID-19

The SOLIUS technology stimulates the production of vitamin D in the skin using a narrow spectrum of ultraviolet B (UVB) light.

Scopio Labs Receives CE Mark for X100 Microscope and Decision Support System With Full Field Peripheral Blood Smear (PBS) Application

Scopio Labs, to date, has demonstrated accurate results on hundreds of patient samples in Tel Aviv Sourasky Medical Center – Ichilov Hospital.

ReViral Announces Grant of Key US Composition of Matter Patent for their Respiratory Syncytial Virus Inhibitor Program

4/8/19: This composition of matter patent claims certain inhibitors of the fusion protein of the respiratory syncytial virus (RSV), including RV521, the Company’s lead pipeline asset. The counterpart to this patent, EP3204375, has also been issued in Europe.

SetPoint Medical Presents Positive Data from its Clinical Study of Bioelectronic Medicine for Treatment of Crohn’s Disease

6/11/18: This open-label study was conducted at five European centers and included 16 patients with moderate to severe Crohn’s disease with inadequate responses to tumor necrosis factor (TNF) antagonist drugs and other non-TNF targeted biologic agents. All patients were implanted with a vagus nerve stimulating device to deliver digital doses of electricity designed to activate the cholinergic anti-inflammatory reflex to produce a systemic immunorestorative effect.

Biocartis Group NV: Study Demonstrates Ability of Idylla(TM) EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests

"Timely communication between oncologists and molecular pathologists is crucial, in particular for acute deteriorating patient clinical management. Our data showed that, when clinical decisions should be taken quickly to save time since days have been spent on waiting for an invalid NGS result, Idylla(TM) can provide a solution," said, Giancarlo Troncone, MD, PhD, Professor of Anatomic Pathology, University of Naples Federico II, Naples, Italy.

Owlstone Medical and Mayo Clinic Collaborate to Develop Pre-Endoscopic Test to Improve Effectiveness of Colonoscopy

Owlstone Medical notes their FAIMS technology is being used in a clinical trial to evaluate its performance as a rapid, point-of-care test to non-invasively assess the adequacy of bowel preparation prior to colonoscopy.